Gilead Sciences Debt/Equity Ratio 2010-2025 | GILD

Gilead Sciences debt/equity ratio for the quarter ending March 31, 2025 was 1.16.

  • Gilead Sciences average debt/equity ratio for 2024 was 1.26, a 16.67% decline from 2023.
  • Gilead Sciences average debt/equity ratio for 2023 was 1.08, a 11.48% increase from 2022.
  • Gilead Sciences average debt/equity ratio for 2022 was 1.22, a 10.29% decline from 2021.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.

Gilead Sciences Debt/Equity Ratio 2010-2025 | GILD

  • Gilead Sciences average debt/equity ratio for 2024 was 1.26, a 16.67% decline from 2023.
  • Gilead Sciences average debt/equity ratio for 2023 was 1.08, a 11.48% increase from 2022.
  • Gilead Sciences average debt/equity ratio for 2022 was 1.22, a 10.29% decline from 2021.

Debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GMAB)$13.3B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Exelixis (EXEL)$10B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Repligen (RGEN)$7.3B
Halozyme Therapeutics (HALO)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B
Bio-Rad Laboratories (BIO.B)$6.3B